However, these results are limited by the size of the patient cohort (n = 31 BC patients), requiring larger, more comprehensive studies to better understand the relationship of B2AR to CAMLs, and possibly their potential as it relates to B2AR-targeted therapies. Here, ADRB2 is linked to breast cancer.